Clovis Oncology

[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
Motley Fool
Tue, 06/27/17 - 09:45 am
AbbVie
biosimilars
Humira
Clovis Oncology
Rubraca
Novartis
Regeneron
Eylea
Is Clovis Oncology A Takeover Candidate?
Seeking Alpha
Mon, 06/26/17 - 04:54 pm
Clovis Oncology
M&A
rucaparib
PARP inhibitors
Look for Clovis Oncology to Resume Its Advance
TheStreet.com
Mon, 03/20/17 - 11:19 pm
Clovis Oncology
Clovis, Tesaro Soar on Astrazeneca Phase Three News
TheStreet.com
Sat, 02/18/17 - 02:37 pm
Clovis Oncology
Tesaro
AstraZeneca
clinical trials
Lynparza
breast cancer
3 Biotechs Likely to Be Acquired in 2017
Motley Fool
Mon, 01/23/17 - 10:18 am
M&A
Clovis Oncology
Intercept Pharma
Jazz Pharmaceuticals
Biotech Stocks: What to Watch in 2017
Motley Fool
Sun, 01/1/17 - 11:33 am
biotech
Seattle Genetics
Exelixis
Clovis Oncology
Kite Pharma
Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug
TheStreet.com
Mon, 12/19/16 - 11:51 am
Clovis Oncology
FDA
PARP inhibitors
rucaparib
ovarian cancer
Rubraca
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Motley Fool
Sun, 12/4/16 - 12:37 pm
biotech
Alnylam
revusiran
Clovis Oncology
rociletinib
Celldex Therapeutics
Rintega
Eli Lilly
solanezumab
Novavax
RSV-F
Arrowhead
ARC-520
ARC-521
ARC-AAT
Biomarin
drisapersen
3 Cancer Drugs That Could Get an FDA OK Next Year
Motley Fool
Mon, 10/10/16 - 09:02 am
FDA
rucaparib
Clovis Oncology
ovarian cancer
binimetinib
Array Biopharma
melanoma
brigatinib
Ariad Pharmaceuticals
non-small cell lung cancer
Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition
TheStreet.com
Fri, 10/7/16 - 04:55 pm
Clovis Oncology
ovarian cancer
rucaparib
Lynparza
AstraZeneca
3 Biotechs That Could Be M&A Targets
Motley Fool
Sat, 09/24/16 - 01:40 pm
biotech
M&A
cancer
Seattle Genetics
Array Biopharma
Clovis Oncology
Takeover Chatter Around Clovis May Be Overdone
TheStreet.com
Fri, 09/23/16 - 10:10 pm
Clovis Oncology
M&A
Eli Lilly
Merck
Takeda
Clovis soars on FDA decision to bypass panel for cancer candidate
Fierce Biotech
Fri, 09/9/16 - 10:24 am
Clovis Oncology
FDA
advisory panels
rucaparib
ovarian cancer
Clovis Jumps as Cancer Drug Gets Priority for FDA Review
Bloomberg
Tue, 08/23/16 - 05:47 pm
Clovis Oncology
FDA
priority review
rucaparib
ovarian cancer
3 Shocking Biotech Flops of 2016 So Far
Motley Fool
Fri, 07/8/16 - 11:01 am
biotech
Rintega
Celldex Therapeutics
glioblastoma
Clovis Oncology
rociletinib
lung cancer
NewLink Genetics
algenpantucel-L
pancreatic cancer
An Overnight Double! Could These Drugmakers Be Next?
Motley Fool
Sat, 07/2/16 - 12:36 pm
Tesaro
ovarian cancer
PARP inhibitors
niraparib
AstraZeneca
Lynparza
Medivation
AbbVie
Clovis Oncology
These 15 Biotech Companies Could Be Takeover Targets
Barron's
Wed, 06/29/16 - 12:56 pm
biotech
M&A
Alder Biopharmaceuticals
Biomarin
Coherus Biosciences
Intercept Pharma
Ultragenyx
Seattle Genetics
Adamas Pharmaceuticals
Alexion
Clovis Oncology
Corbus Pharmaceuticals
Incyte
Prothena
Puma Biotechnology
Tesaro
Versartis
Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting
Yahoo
Mon, 06/6/16 - 11:04 am
Clovis Oncology
rucaparib
ovarian cancer
pancreatic cancer
ASCO 2016
2 FDA Decisions To Watch In June
Seeking Alpha
Wed, 06/1/16 - 10:54 am
FDA
rociletinib
Clovis Oncology
KemPharm
Apadaz
After shutting down cancer drug, Clovis now facing government investigations
BioPharma Dive
Fri, 05/13/16 - 10:15 am
Clovis Oncology
rociletinib
FDA

Pages